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Osteosarcoma (OS) is one of the most common primary malignant bone cancer in children 
wherein the mortality rate within 5 years is 30% and patients suffer from bone pain, limited or loss 
of limb function, or fatigue. In addition, OS is one of the most widespread cancers in companion 
dogs, particularly larger breeds, and closely resembles human OS. Unfortunately, in over 30 years, 
there has been no significant advancement in treatment options in humans; and canine treatment 
options are also limited. The cation independent mannose-6- phosphate/insulin-like growth factor-
2 receptor (IGF2R) was found to be consistently overexpressed on multiple standard OS cell lines, 
including patient-derived xenografts, as well as on tumors from dogs with OS, making it a 
promising therapeutic target for radioimmunotherapy (RIT). RIT involves the use of an antibody 
labeled with an alpha- or beta- emitting radioisotope which delivers cytotoxic radiation to targeted 
cells. Our objective is to develop a novel, effective and safe treatment for OS using RIT using a 
comparative oncology approach. Antibodies against IGF2R were developed using phage-display, 
a combinatorial protein engineering technique wherein bacteriophages are used to select for high 
affinity reagents. The IGF2R-specific antibodies were tested in vitro by performing ELISA and 
flow cytometry and were also tested in vivo by performing microSPECT/CT imaging which 
confirmed that the antibody bound to the OS tumors in mice. This was followed by therapy studies 
which involved the testing of the IGF2R-specific antibody radiolabeled with Lutetium-177, a β-
emitting theranostic radioisotope, for therapeutic efficacy studies in mouse models of human and 
canine OS. Future studies will involve a clinical trial in canine OS patients. The development of 
IGF2R-specific RIT will lead to a better therapeutic strategy for not only human OS but also for 
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Osteosarcoma (OS) is one of the most common primary malignant bone tumor wherein its 
incidence is more prevalent in children and adolescents. The overall 5-year survival rate of 
individuals with OS is approximately 60% (“Osteosarcoma - Childhood and Adolescence: 
Statistics”, 2021) and those with metastatic disease have much poorer outcomes (Mirabello et al., 
2009; “Osteosarcoma - Childhood and Adolescence: Statistics”, 2021). Moreover, OS survivors 
still suffer from general health related issues, chronic medical condition, and permit life-long 
follow-ups for second malignant neoplasms (Nagarajan et al, 2011). In addition, OS is one of the 
most widespread cancers in large breed companion dogs and closely resembles human OS wherein 
gross and histopathologic architecture are comparable and similar metastatic rates and origin of 
the cancer are observed.(Mueller et. al., 2007; Simpson et al, 2017). Unfortunately, in over 30 
years, there has been no significant advancements in finding new treatment options for OS and 
canine treatment options are also limited. Although therapies such as chemotherapy and radiation 
therapy are available and have reasonable efficacy, patients’ response rate and survival time are 
variable and can be difficult to predict. Moreover, OS has a broad genetic variability from one 
tumor to the next (Czarnecka et al., 2020), making it challenging to pursue conventional therapies.  
Targeted radionuclide therapy (TRT) is a type of therapy which involves a radioactive drug 
that targets specific cells with high precision and delivers cytocidal radiation in the form of alpha- 
or beta- emitting radionuclides. TRT also avoids side effects of external beam radiation therapy 
(EBRT) in which healthy cells surrounding the affected area are also destroyed.   
Radioimmunotherapy (RIT) is a subset of TRT, which uses antibodies as the delivery agent of 
cytotoxic radionuclides towards the target cells.  
Cation independent mannose-6-phosphate/insulin-like growth factor-2 receptor 
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(M6PR/IGF2R) is a receptor that was found to be consistently overexpressed on multiple standard 
and patient-derived OS cell lines as well as on canine OS tumors making it a promising therapeutic 
target for RIT (Hassan et al., 2012; Geller et al, 2016; Karkare et al., 2019).  A study published in 
2016 has shown promising results using RIT in treating OS mouse xenograft models (Geller et al., 
2016). In this study, the mouse monoclonal antibody (mAb), MEM-238, which targets human 
IGF2R, was radiolabeled with Rhenium-188 (188Re), a beta-emitting radionuclide. Suppression of 
the tumor growth was observed in animals treated with RIT compared to the untreated ones. 
Moreover, another study published in 2019 (Karkare et al, 2019) has shown the same result with 
a different antibody, 2G11, that is cross-reactive with both human and murine IGF2R. The 2G11 
mAb was radiolabeled with Lutetium-177 (177Lu), a beta-emitting radioisotope, and has shown 
that RIT significantly slowed down the growth of human OS tumors in mice without significant 
local and systemic toxicity.  
As we progress towards developing a new form of treatment for OS, our goal is to develop a 
fully human IGF2R-specific mAbs that are cross-reactive to human, murine and canine versions 
of the IGF2R protein. This will allow a comparative oncology approach for simultaneous 
development of RIT for both human and canine patients. A sequence alignment of the human, 
murine, and canine IGF-II ligand binding region showed that this region is highly conserved 
among these species with 82% sequence identity (Broqueza et al, 2021). The IGF2R-specific 
human antibodies for this project were developed using phage-display, a combinatorial protein 
engineering technique wherein bacteriophages are used to select for high affinity reagents. The 
IGF2R-specific antibodies were radiolabeled with Indium-111 (111In) for micro-single photon 
emission computed tomography (SPECT)/computed tomography (CT) imaging to confirm 
accumulation of antibody in OS tumors in vivo. This was followed by therapy studies with the 
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therapeutic radionuclide, 177Lu, which involved the testing for therapeutic efficacy in mouse 
models of human and canine OS.  
This project aims to develop a novel treatment for OS based on RIT, by generating IGF2R-
specific monoclonal antibodies using the phage-display technique and using the comparative 
oncology approach. This will lead to new strategies to treat not only human OS but also OS of our 
non-human family members as well. 
 
2.0 LITERATURE REVIEW 
2.1 Primary Bone Cancer 
Sarcoma refers to cancers that arise from tissues embryologically derived from the 
mesenchyme, such as the bone or in the soft tissues, also called as connective tissue, in the 
body. Bone sarcoma can arise in any part of any bone and begins once an accumulation of 
mutations, either spontaneous or induced secondary to carcinogens, is sufficient to transform 
healthy cells into neoplastic cells, creating a mass of tissue of abnormal cells called a tumor. 
A tumor may be benign or malignant. A benign tumor can grow, however, it does not spread 
to other parts of the body, but it can still weaken the bone and predispose a patient to a bone 
fracture at the site of the mass. (“Bone Cancer (Sarcoma of Bone): Introduction”, 2020). An 
example of a benign bone tumor is osteoma which typically forms on the skull but can also 
develop on the long bones of the body such as the femur and tibia. A malignant tumor, on the 
other hand, can spread to other parts of the body through a process known as metastasis. An 
example of metastatic tumor is osteosarcoma. 
Primary bone sarcoma is a cancer that originates from the cells of the bone itself, which 
mainly comprises of osteoblasts. It does not include cancer that has metastasized and occurs 
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more often in male than female where it has been estimated that 2100 male and 1510 females 
will be diagnosed with primary bone sarcoma in the United States in the year 2021 (“Bone 
Cancer (Sarcoma of Bone): Statistics”, 2021). Patients suffering from primary bone sarcoma 
have an increased chance of getting a bone fracture as local tumor growth of the cancer leads 
to the destruction of the adjacent normal bones. 
There are different types of primary bone sarcomas which includes chondrosarcoma, 
chordoma. Ewing’s sarcoma, and osteosarcoma (Table 2.1). 
 
 
Table 2.1. 5-year survival rate (%) of patients with primary bone sarcoma. Information 
gathered from “Bone Cancer (Sarcoma of Bone): Statistics”, 2021. 
    5-year survival rate (%) 
Bone Cancer 
Type Definition Overall 









If cancer has 
metastasized to 
distant parts of 
the body 
Chondrosarcoma 
cancer of the 
cartilage 78 91 75 22 
Chordoma 
cancer of the 
tissue in the 
spinal cord 82 87 83 55 
Ewing’s sarcoma 
cancer that 
develops in the 
bone or soft 
tissue 62 82 67 39 
Osteosarcoma 
cancer of bone-
forming cells 60 74 66 27 
 
For OS, the World Health Organization (WHO) has divided the histological 
classification of bone tumors into central, intramedullary, and surface tumors. Each group has 
its subtypes. An example of this is conventional OS which is a subtype of central OS and 
represents 80% of all OS cases in children and adolescents (Misaghi et al, 2018). Conventional 
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OS can further be subdivided into osteoblastic, fibroblastic, and chondroblastic groups 
depending on the principal features of the cell.  Another subtype which falls under the 
classification of surface OS is parosteal OS which is a low-grade OS that arises from the 
periosteum and represents 4-6% of OS (Misaghi et al, 2018). 
 
2.2 Osteosarcoma 
Osteosarcoma (OS) is a primary bone tumor which develops from neoplastic/malignant 
transformation of osteoblasts that are typically found in variably mature stages within the 
lesion.  Lesions most often arises in active metaphyses of the long bones such as distal femur, 
proximal tibia, and proximal humerus. However, the cancer can also originate in flat bones of 
the pelvis, skull, ribs and in the spine (Anderson et al, 2020). 
Although primary bone cancer is rare, osteosarcoma is one of the most common primary 
bone sarcomas especially in children and adolescents, making up 2% of all cancers in children 
and 3% in teens (“Osteosarcoma - Childhood and Adolescence: Statistics”, 2021). According 
to a study published in 2009, the incidence of OS in children and adolescents is relatively 
consistent around the world (Mirabello et al., 2009). The study found that the occurrence of 
OS peaked at younger ages in females in comparison to males. However, in most countries, 
OS was more common in males than females. Moreover, from 1973 to 2004, the incidence of 
the bone cancer was found to be increased in the youngest age group, variable in middle age 
group and decreased in the elderly (Mirabello et al., 2009). 
The cause of OS is still unknown but there are some risk factors that increases a person’s 
chance of getting the disease such as hereditary disorders including but not limited to 
retinoblastoma, Li-Fraumeni syndrome, and Werner syndrome (Ritter and Bielack, 2010; 
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“Osteosarcoma - Childhood and Adolescence: Risk Factors”, 2021; Czarnecka, et al, 2020). 
It has also been previously shown that a single nucleotide polymorphism (SNP) within a 
haplotype block also increases the chances of developing OS (Savage et al., 2007). 
 The 5-year survival rate for children with OS is 68% and decreases with the development 
of metastatic disease, with the rate dropping to 27% once the cancer spreads to distant parts 
of the body from the site of disease (“Osteosarcoma - Childhood and Adolescence: Statistics”, 
2021). The survival rate for OS patients depends on many different factors including the type 
and subtype of cancer, the time the cancer was diagnosed, the site and size of the tumor, the 
development of local recurrence and the cancer response to treatment (Davis et al., 1994; 
“Osteosarcoma - Childhood and Adolescence: Types of Treatment”, 2019) 
 
2.2.1 Diagnosis and Treatment 
A suspected OS evaluation starts with the patient’s full history, physical examination, and 
plain radiographs. The first diagnostic test for detection of OS involves a preoperative imaging 
protocol for any suspected bone lesion which includes an X-ray of the whole bone and adjacent 
joint (Misaghi et al., 2018). Additional tests are also a critical part of OS diagnosis and staging. 
Magnetic resonance imaging (MRI) can evaluate the lesion’s invasion into the soft tissue and 
neurovascular structures. However, this test can rule out the metastases of the cancer 
(“Osteosarcoma: An Introduction”, 2012.). A chest x-ray and chest CT scan can be done to 
detect lung metastases and a bone scan of the body can show the distant spread of the disease. 
Another test that is essential to the diagnosis of OS is the biopsy of the tumor as it provides 
definite characteristics of the tumor tissue which helps determine whether the tumor is high 
grade (highly malignant) or low grade (Misaghi et al., 2018; “Osteosarcoma: An 
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Introduction”, n.d.; “Osteosarcoma - Childhood and Adolescence: Diagnosis”, 2019). 
For treatment decision-making, grade is one of the most important factors. Most 
musculoskeletal surgical oncologists refer to the staging system adopted by the 
Musculoskeletal Tumor Society (MSTS) in 1980 (modified in 1986) (Anderson et al, 2020). 
There are two histologic grades for malignant tumor: low-grade and high-grade. A low-grade 
malignant tumor refers to tumors that recur in the same localized and has a 25% or less 
probability to metastasize whereas high-grade tumors have a significantly higher chances of 
metastasizing to different parts of the body and requires a more notable procedure or therapy 
(Anderson et al, 2020). In children, most of the osteosarcoma tumors are high-grade 
(“Osteosarcoma - Childhood and Adolescence: Introduction”, 2019).  
OS is treated with a combination of therapies which includes neoadjuvant and adjuvant 
chemotherapy, surgery, and radiation therapy (Misaghi et al., 2018; “Osteosarcoma: An 
Introduction”, 2012).  Methotrexate with leucovorin rescue, doxorubicin, cisplatin, and 
ifosfamide are the four standard chemotherapy agents that are almost in all treatment regimes 
(Misaghi et al., 2018). Dose intensity is important as well. A study published in 2009 found 
an increase in mortality rate in patients who waited over twenty-one days to restart 
chemotherapy. They suggest resuming chemotherapy within the first twenty-one days post-
operation to maintain dose intensity (Imran et al., 2009). 
Further treatment for OS is surgery which can be divided into limb salvage and amputation. 
Limb salvage gives 85-90% OS patients a safe methodology of treatment which includes two 
essential steps: 1) resection and 2) reconstruction. Resection plays a role in the elimination of 
the disease as it includes excision of previous biopsy sites and tract whereas reconstruction 
has two forms: endoprosthetic replacement wherein the design of the implants includes 
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modular and custom-made; and biologic replacement which includes allograft, autograft, 
recycled autografts, and allografts (Misaghi et al., 2018). On the other hand, amputation used 
to be the standard surgical treatment of OS, however, it is now reserved to non-resectable 
tumor with soft tissue and neuromuscular contamination (Misaghi et al., 2018). Moreover, 
some studies have shown that patient who have undergone limb salvaging have higher survival 
rate than people who had amputation (Grimer et al., 2002). 
The third treatment option is radiation therapy. However, it is not widely used in OS 
treatment due to its association with risk of infection, nevertheless, it is occasionally 
recommended when the tumor is difficult to surgically remove or residual tumors remain after 
surgery (Misaghi et al., 2018); “Osteosarcoma: An Introduction”, 2012). 
 
2.2.2 Canine Osteosarcoma 
Canine OS is one of the most widespread cancers in dogs with its incidence rates 27 times 
higher than in people (Simpson et al., 2017). It has the same phenotype as human OS in 
children and occurs mostly in larger breeds with the appendicular skeleton most affected.  
Osteosarcoma in dogs is often painful and its signs and symptoms may be subtle. Lameness 
and swelling of the site of the disease are the common signs of OS. In addition, OS can lead 
to deformity, depending on the location of the tumor (Ehrhart et al, 2013). Canine patients 
suffering from OS are also at risk of pathological fractures due to lesion-related bone 
destruction (Poon et al, 2020)  
To diagnose OS in canine, veterinarians take radiographs of the suspected primary site and 
perform physical examinations. Definitive diagnosis may be obtained by performing fine 
needle aspiration which involves suctioning a sample of tissue directly from the lesion using 
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a syringe and analyzing them under the microscope (Stoewen and Pinard, n.d.) by a 
cytopathologist. A bone biopsy may be used to validate OS if the aspiration procedure is not 
diagnostic. Biopsy may be done as  open incisional, closed needle or as a trephine biopsy 
(Ehrhart et al, 2013). An open incision biopsy can be beneficial due the large amount of 
sample collected, however, this can be outweighed by an increase in postsurgical complication 
in canine patients such as infection and hematoma formation (Ehrhart et al, 2013).  A trephine 
biopsy, wherein a small piece of bone is collected with the marrow inside, is also an advantage 
for diagnosing a patient as it yields 93.8% accuracy rate. Nonetheless, this technique can 
increase the risk of creating pathologic fractures. A closed biopsy can also be an option which 
uses a Jamshidi needle to collect bone marrow. Jamshidi biopsy has an accuracy rate of 91.9% 
for detecting tumors and 82.3% accurate rate for classifying a tumor subtype (Ehrhart et al, 
2013).  
Thoracic radiographs, blood tests, and a urinalysis can also be performed to check the 
overall health of the dogs and to help assess if the cancer has metastasized to other parts of 
the body (“Bone Cancer in Dogs”, n.d.). The examination of the spread of the disease is 
important in patient disease staging. It is difficult to detect pulmonary metastasis by 
radiographs and most dogs will have undetectable micro metastatic disease, leading to a poor 
prognosis in canine OS (Poon et al, 2020). Although it is difficult to determine at the time of 
diagnosis whether the cancer has metastasized, advanced imaging such as CT, MRI, PET/CT 
may be used as a tool in patient staging (Ehrhart et al, 2013).  
Treatment of canine OS typically involves amputation of the affected limb followed by 
chemotherapy to help control the disease and target metastasis (“Bone Cancer in Dogs”, n.d.; 
Stoewen and Pinard, n.d.). Many dogs cope well after amputation and most dog owners are 
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also satisfied with their pets’ quality of life. (Ehrhart et al, 2013). However, amputation may 
not be suitable for some canine patients such as those who have concurrent neurological 
problems or severe arthritis (“Canine Osteosarcoma Fact Sheet,”, n.d.). In the case amputation 
is not appropriate, limb-sparing surgery can be performed where the primary tumor is removed 
with marginal resection (Ehrhart et al, 2013). Stereotactic radiation (SRS/SRT) can also be 
considered if surgery is not optional due to tumor location (“What You Should Know about 
Osteosarcoma (Bone Cancer) in Dogs”, n.d.). SRS offers the advantage of having a non-
surgical procedure that delivers high dose of radiation to the tumor and sparing normal tissues. 
Moreover, canine patients who undergo this procedure result in a good to excellent limb 
function. However, SRS may not be readily available to veterinarians and there is also the 
case of the patient developing post irradiation pathologic fracture (Ehrhart et al, 2013). 
Nevertheless, it is still a good non-surgical limb-sparing alternative. 
 












RIT is a subset of TRT wherein an antibody is radiolabeled with an α or β - emitting 
radionuclide. The radiolabeled antibody delivers cytotoxic radiation to the targeted cells, 
killing them by damaging their DNA, making the cells unable to grow and divide. One of the 
advantages of RIT is that it is independent of any specific pathway. Moreover, it is not affected 
by resistance mechanisms or tumor microenvironmental fluctuations (Lerner, 2016; Milenic 
et al., 2004). There are three types of radiation that are integral for TRT: photons, electrons 
and α-particles.  
Photons are often present in the form of X-rays or γ-rays. The benefit of radionuclide 
photon emissions is that the photon energy is high enough to penetrate soft tissues making it 
ideal for imaging but insufficient to initiate double stranded DNA breaks and induce apoptosis 
in cells on a consistent basis which is required for therapeutic isotopes (Sgouros et al., 2020). 
Such isotopes include technetium-99m and indium-111. 
Electron emission includes Auger electrons and β-particles. Auger electrons are produced 
as an emission during suborbital electron transitions and are very short-ranged. They can be 
highly toxic to the cells if the radiopharmaceutical drug localizes in the nucleus. β-particles, 
on the other hand, emit electrons from the nucleus and have a longer range in tissues.  β-
emitters are commonly used for radiopharmaceutical therapy as they are widely available and 
also emit photons that can be used for imaging (Sgouros et al., 2020). b-emitting isotopes 
include lutetium-177, yttrium-90, and iodine-131. 
α-particles are helium nuclei that consists of two protons and two neutrons. They are 
emitted from a radioactive atom and are short-range. They are positively charged and have 
higher energy compared to electrons. Unlike β-particles or γ-rays, α-particles are unable to 
penetrate most materials and are required to be in close proximity to the target to deliver their 
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radioactive payload. On the other hand, their linear energy transfer, meaning the amount of 
energy transferred by an ionizing particle per unit distance, is 400 times greater than electrons 
(Sgouros et al., 2020). These characteristics make α-particles a promising avenue for 
radiopharmaceutical therapy, with the increasing use of a-emitting radioisotopes such 
actinium-225 and radium-223. 










Several variables should be considered for RIT such as the target antigen, the targeting 
antibody, and the radionuclide. An ideal target should be minimally expressed on normal cells 
but highly expressed at a uniform density on the surface of tumor cells. Whereas an ideal 
targeting antibody should penetrate tumor nodules rapidly, has high binding avidity to the 
target antigen, have minimal interaction with non-malignant tissues, and should be cleared 
from blood circulation after maximal tumor binding is achieved (Green et al., 2002). In terms 
of radioisotopes, solid and bulky tumors can be treated with radionuclides emitting long-
Radionuclide Therapeutic Emission Half-life
Bismuth-213 α 46 minutes
Actinium-225 α 9.92 days
Radium-223 α 11.4 days
Astatine-211 α 7.2 hrs
Rhenium-188 β 17 hrs
Samarium- 153 β 1.9 days
Holmiun-166 β 26.8 hrs
Copper-67 β 61.83 hrs
Iodine-131 β 8 days
Ytrrium-90 β 64 hrs
Lutetium-177 β 6.65 days
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ranged β particles, whereas small clusters of cancer cells can be targeted with short-ranged α-
particles (Zaheer et al., 2019).  
 
Table 2.3. Partial list of radiopharmaceutical drugs currently approved by the FDA and in clinical 
trials. Information obtained from Sgouros et al., 2020 and “FDA-approved radiopharmaceuticals”, 
n.d. 
Radiopharmaceutical Trade name Indication Development-phase 
Radium-223 
dichloride 
Xofigo Treatment of patients with bone 
metastases and castration-resistant 
prostate cancer 
FDA-approved 
Gallium-68 dotatate NETSPOTS PET imaging for  localization of 





Zevalin Treatment of Non-Hodgkin's 
lymphoma 
FDA-approved 























Treatment of prostate cancer Phase III 
Holmium-166 
 
Treatment of hepatic malignancies Phase II 
Actinium-225 aCD38 
 
Treatment of multiple myeloma Phase I 
Iodine-131 CLR 131 
 
For paediatric cancer; Head and neck 





2.4 Generating monoclonal antibodies using phage-display 
In addition to traditional chemotherapy and radiotherapy, targeted therapy using 
monoclonal antibodies (mAbs) is an effective method of therapy for several cancers (Castelli 
et al., 2019). MAbs can be conjugated with toxins and radionuclides to improve potency. 
Therefore, there is immense interest in generating mAbs that bind to biomarkers of cancers in 
general, and specifically in our case, OS. Traditionally, antibodies are generated using the 
hybridoma method in mice (Doevendens and Schellekens, 2019). There are significant issues 
of immunogenicity due to the foreign origin of these antibodies and they often induce humoral 
immune response in patients. Development of murine antibodies for therapy will require 
extensive optimization to de-immunize these molecules through a process known as 
humanization (Almagro et al., 2018). Recent developments in protein engineering include 
transgenic mice that have human immunoglobulin genes (Brüggemann et al., 2015) and in 
vitro methods, such as phage-display (Fellouse and Sidhu, 2007; Lerner, 2016; Kehoe and 
Kay, 2005). These methods now allow for the development of human antibodies in vitro and 
in vivo, with theoretically no immunogenicity to human patients.  
Phage-display is a combinatorial protein engineering technique where the antigen-binding 
fragment (Fab) regions of the antibody are expressed as a fusion coat protein of 
bacteriophages. Each bacteriophage virion encodes the Fab sequence in its genome and 
displays the corresponding Fab fragment of the antibody on its surface. A large library 
consisting roughly 1010 Fab variants, mimicking the immune repertoire, are constructed such 
that each virion encodes and expresses a single variant of the Fab. These constructed libraries 
are subsequently screened against target proteins of interest (Kehoe and Kay, 2005).  
15 
 
Monoclonal antibodies formats commonly used for therapy belong to the immunoglobulin 
G (IgG) isotype. The structure of the IgG molecule is comprised of four polypeptide chains. 
It consists of two identical 50 kDa heavy chain and two identical 25 kDa light chains forming 
a heterotetramer. These chains are usually linked by inter-chain heavy chain cysteine disulfide 
bonds. The heavy chains consist of an N-terminal variable region (VH) and three constant 
domains (CH1,CH2,CH3) whereas the light chains consist of N-terminal variable region (VL) 
and a constant domain (CL). The association of the light chain with the VH and CH1 domains 








     Figure 2.2. Structure of an immunoglobulin G (IgG) 
The antigen binding region of the Fab consists of six complementary determining regions 
(CDRs). The CDRs consists of amino acid loops of different sizes and composition. The principle 
behind molecular recognition of target protein is the ability of a combination CDRs to form a new 
protein interaction interface that generates a perfect match in shape and biochemical 
complementarity to the target. By screening billions of potential Fab fragments in the 
bacteriophage library against the IGF2R protein, we expect to find Fab fragments that bind with 







Figure 2.3. A schematic diagram of the generation of antibody libraries using phage-display 
technique. 
 
To select target-specific mAbs, the library consisting of billions of variants of Fabs is used 
for a process called selection wherein recombinant proteins are coated on NUNC Maxisorp 
plates (Kehoe and Kay, 2005). For this project specifically, we generated recombinant IGF2R 
domains 11-14 as a soluble Fc fusion (Broqueza et al, 2021). The phage Fab library was 
depleted by allowing the phage library to bind to the Fc region of the antibody to remove non-
specific binders. The unbound phage was then transferred to the plates coated with the 
recombinant human, murine, and canine IGF2R proteins to get IGF2R-specific binders. The 
bound phage antibodies were then collected, amplified and were used for the subsequent 
rounds of selection. Three to four rounds of selection were conducted to get Fab fragments 
that are highly specific and have high affinity towards the IGF2R protein from human, murine 
and canine origin (Broqueza et al, 2021).  
To enable radiolabeling and subsequent use in imaging and RIT, the antibody needs to 
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be conjugated with a bifunctional chelator, such as CHXA”, which links the antibody to the 
radioisotope. The isothiocyanate group of the chelator binds to the lysine residues of the 
antibody. Once conjugated to the antibody, the chelator acts as a claw and holds the 









Figure 2.4.  Radiolabeling of an antibody.  
 
3.0 HYPOTHESIS AND OBJECTIVES 
Hypothesis: As canine OS closely resembles human OS, we hypothesize that IGF2R-specific 
human antibodies can be generated that would effectively target human and canine OS tumor cells 






1. To create a panel of IGF2R-specific human mAbs for targeting IGF2R in OS. These mAbs 
will be tested for their ability to bind in vitro to human and canine OS cell lines. The most 
selective antibodies will be evaluated for their ability to concentrate in OS in mouse 
models in Aim 2. 
2. To perform microSPECT/CT imaging and biodistribution of the radiolabeled mAbs in 
mice bearing human and canine OS tumors. Select the antibody with the highest tumor 
uptake for radioimmunotherapy in Aim 3. 
3. To characterize OS tumor response using radioimmunotherapy in human and canine OS 
tumors in mouse models and to assess the safety of such treatments. 
 
4.0 MATERIALS AND METHODS 
4.1 Reagents and Antibodies 
The murine mAb, 2G11, that was used as a positive control in flow cytometry 
experiments was purchased from Thermofisher (Vancouver, BC, Canada). Human mAb 
against respiratory syncytial virus (RSV), Palivizumab, that was used as negative isotype 
control was obtained from MedImmune.(Gaithersburg, MD, United States). Silica gel 
instant thin layer chromatography (SG-iTLC) strips that was used to determine percentage 
labelling of the radiolabeled antibodies were acquired from Agilent (Mississauga, ON, 
Canada). (R)-2-Amino3-(4-isothiocyanatophenyl)propyl]-trans-(S,S)-cyclohexane-1,2-
diamine-pentaacetic acid (CHXA”) bifunctional chelating agent was acquired from 
Macrocyclics (Dallas, TX, USA). The radioisotope 111In was purchased from BWXT ITG 
Canada, Inc. (Ottawa, ON, Canada); and 177Lu from Radiomedix (Houston, TX, USA). 
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4.2 Cell Lines 
Human OS cell line, 143B, and canine OS cell line, D17, were purchased from 
American Type Culture Collection (ATCC) (Manassas, VA, USA). OS-33, a well 
characterized patient-derived human OS cell line, was a kind gift from Dr. R. Gorlick (MD 
Anderson Cancer Center, Houston, TX, USA) whereas canine patient derived OS cell lines, 
Gracie and McKinley, were a kind gift from Dr. Doug Thamm’s lab at Colorado State 
University School of Veterinary Medicine (Maeda et al, 2012). The 143B cells were 
cultured in Eagle’s Minimum Essential medium (Hyclone, Cat. No. SH30024.01) and 
OS33 cells were cultured in Dulbecco’s Modified Eagle Medium (Hyclone, Cat. No. 
SH30243.01). Both media were supplemented with 10% FBS (Hyclone, Cat. No. 
SH30396.03), 1% antibiotic-antimycotic Solution (100×) (Gibco, Ref. 15240-062)) and 
1% MEM Non-Essential Amino Acids Solution (100X) (Gibco, Ref. 11140-050).  Gracie 
and McKinley cells were cultured in RPMI-1640 with HEPES (Hyclone, Cat. No. 
SH30255.01) and was supplemented with 10% FBS, 1% antibiotic-antimycotic Solution 
(100×) and 1% MEM Non-Essential Amino Acids Solution (100X), and 1% sodium 
pyruvate (Hyclone, Cat. No. SH30239.01). 
 
4.3 Expression of IGF2R-specific Full Length IgG1 Antibodies in Human Mammalian 
Cells 
The variable light chain (VL) and variable heavy chain (VH) coding sequences of the 
lead antibodies were cloned in pFUSE2ss-CLIg-hK vector and pFUSE2ss-CHIg-hG1 
vectors respectively (Invivogen). Previously described protocol (Vazquez-Lombardi et al, 
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2018) was used to transiently express the clones in Expi293F mammalian cells. The 
expressed antibodies were purified by protein A affinity chromatography using 
MabSelectSure (GE Healthcare) affinity resin, using manufacturer recommended 
protocols. 
 
4.4 ELISA of Purified IgG1 against Recombinant IGF2R  
NUNC Maxisorp 96-well plate was coated overnight with 50 ul 3 µg/ml (in 1xPBS) 
of recombinant human, murine and canine IGF2R, coating each well with 0.15 µg of 
protein. The wells were blocked with 100 µl of  PB Buffer (1× PBS + 0.2%  BSA) and left 
for one hour at room temperature. The plate was then washed twice with PT buffer (1× 
PBS + 0.05% Tween20). Purified IgG1s (IF1 and IF3) diluted in PBT buffer (1× PBS + 
0.2% BSA + 0.05% Tween20) were added to the corresponding wells at different 
concentrations ranging from 0.1 to 100 nM and was incubated at room temperature while 
shaking. After one hour, the plate was then washed four times with PT Buffer. Secondary 
antibody, Goat Anti-Human Kappa (K) Light Chain Antibody HRP (Invitrogen), was 
diluted (1:5000) in PBT buffer and 50 µL was added to each well and was incubated for 
45 min at room temperature while shaking. After incubation, the plate was then washed 
with PT buffer four times. The plate was then developed with 45 µL of TMB (3,3', 5,5”-
tetramethylbenzidine) substrate (1 Peroxidase Substrate: 1 TMB Peroxidase Substrate) 
(Seracare, Milford, MA, USA) for ~5 min. Reaction was terminated using 45 ul of 1 M 




4.5 Flow Cytometry on Human and Canine OS cells 
A 96-well U-shape titration plate containing 300,000 cells in each well were incubated 
with the primary antibody (either 2G11, RSV, IF1, or IF3) with concentrations ranging 
from 3 nM to 300 nM. The cells were incubated with the primary antibody in FACS buffer 
(1× PBS + 0.5% BSA or 2% FBS + 0.02% azide) at room temperature for half an hour. 
Plate was then washed twice with FACS buffer before the addition of the secondary 
antibody. Goat anti-Human IgG Fc (PE) (eBioscience, cat. #12-4998-82) was used as the 
secondary antibody for the IF1, IF3 and RSV antibodies whereas Goat Anti-Mouse IgG2a 
H&L (PE) from Abcam (ab74490) was used as a secondary for 2G11. The secondary 
antibodies were incubated for 30 mins at room temperature. Cells were then washed again 
three times with FACS buffer and was then read and analyzed in the CytoFlex machine. 
 
4.6 Animal Model 
Female nude mice from Charles River Laboratories were (Wilmington, MA, USA) 
were used initially in pilot experiments. Female SCID (CB17/Icr-Prkdcscid/IcrIcoCrl) 
mice aged six-eight week old obtained from Charles River Laboratories were used for the 
biodistribution and therapy experiments. Mice were anesthetized with 2.5-5% isoflurane 
with a 1 L/min oxygen flow rate for tumor induction and were injected subcutaneously 
with 4 million cells of either 143B, OS33, Gracie or McKinley cells into the right flank of 
the mouse. Mice were monitored for weight and tumor development and were imaged or 




4.7 Conjugation of Bifunctional Chelating Agent, CHXA”, and radiolabeling of the 
antibodies 
Before radiolabeling the antibodies, one milligram of IF1 and IF3 antibodies were 
conjugated with 2.5x or 10x initial excess CHXA” by loading the antibodies in 30K MW 
(molecular weight) Amicon Ultra 0.5 mL centrifugal filter (Millipore Sigma) and buffer 
exchanging into 1x conjugation buffer. To make the 1x conjugation buffer, 1 ml of 10X 
Conjugation Buffer buffer (0.05 M Carbonate/Bicarbonate, 0.15 M NaCl, 5 mM EDTA, 
pH 8.6 - 8.7) was combined with 100 µl 0.5 M EDTA, pH = 8.0 and was diluted to 10 mL 
with deionized water. The buffer exchange was performed by doing 10x 0.5 ml washes in 
a refrigerated centrifuge at 4°C at 14.0 xg for 3 minutes per spin. The antibody was 
recovered from the Amicon filter and fresh 2 mg/ml CHXA” was prepared by dissolving 
the CHXA” powder in 1x conjugation buffer. CHXA” solution was then added to the 
antibody to provide either 2.5-fold or 10-fold molar equivalents of CHXA”. The reaction 
mixture was incubated at 37°C for 1.5 hours with shaking. The conjugated antibodies were 
then purified with 0.15 M ammonium acetate buffer (pH=6.5-7.0) by performing ten 0.5 
ml washes on Amicon concentrators in a refrigerated centrifuge at 4°C. Samples were then 
stored at 4°C. 
For the biodistribution study, antibodies were radiolabeled with Indium-111 (111In) 
at a specific activity of 5:1 μCi/μg of the antibody. For imaging and therapy, the antibodies 
were conjugated at 10:1 μCi/μg specific activity. 111In was used for the imaging 
experiments whereas Lutetium-177 (177Lu) was used for the therapy study. 111In or 177Lu 
chloride was added to 0.15 M ammonium acetate buffer and conjugated antibody was 
added to the solution. The reaction mixture was incubated for 45 minutes at 37°C with 
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shaking. The reaction was then quenched by adding 3 μl of 0.05 M EDTA solution. The 
radiolabeling percentage was measured using SG-iTLC strips using 0.15 M ammonium 
acetate buffer as the solvent phase. The SG-iTLC strips were cut in half and was read on a 
Perkin Elmer 2470 Automatic Gamma Counter wherein the top half contains the unlabeled 
radioisotope and the lower half containing the radiolabeled antibody. The percentage of 
radiolabeling yield was calculated by dividing the counts per minute (CPM) of the bottom 
half by the sum of the cpm of both the top and half bottom of the strip. Radiolabeling yields 
were greater than 90%. To achieve 99% of the radiolabeled antibodies, the radiolabeled 
antibodies were purified on size exclusion spin filters by performing three washes with 
PBS to remove excess unlabeled isotopes. High-performance liquid chromatography 
(HPLC) was used to analyze the radiochemical purity of the radiolabeled antibody.  
 
4.8 MicroSPECT/CT imaging of mice bearing Human and Canine OS tumors 
Female SCID mice were subcutaneously injected with 4 million cells of either 143B, 
OS33, or Gracie cells. Once tumors were palpable and reached approximately 10 x 10 mm, 
mice were intravenously injected with 200 μCi of 111In-IF3 with the radiolabeled antibody 
prepared using an initial 2.5 molar excess of CHXA”. Mice were then imaged at the prone 
position at 24 and 48 hour post-injection. MILabs VECTor4 (Utrecht Netherlands) 
microSPECT/CT scanner was used to collect the microSPECT/CT images and was 
processed using the software package PMOD (version 3.9, PMOD Technologies, Inc, 
Zürich, Switzerland). CT data was collected for 5 minutes whereas the SPECT data was 
collected for 20 mins using Extra Ultra High Sensitivity Mouse (XUHS-M) collimator. All 
SPECT images were reconstructed with MILabs reconstruction software using both 245 
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keV and 171 keV 111In gamma emissions on a 0.4 mm voxel grid.    
 
4.9 Biodistribution Study 
For the full-scale biodistribution study of IF1, female SCID  mice bearing 143B 
tumors were randomized and were injected intraperitoneally with 30 µCi of  111In -IF1 with 
a 10 molar excess of CHXA”. Mice from each group were sacrificed at 24 and 72 hour 
post-injection and organs were collected including blood, tumor, heart, lungs, pancreas, 
spleen, kidney, liver, brain, stomach, small intestine, large intestine, thigh muscle and bone. 
Organs were weighed and radioactivity was counted in a gamma counter (Perkin Elmer, 
Waltham, MA, USA). The percentage injected dose per gram (%ID/g) was then calculated 
using a dilute standard. 
For the small-scale biodistribution of IF1 vs IF3, non-bearing healthy SCID mice were 
injected intraperitoneally with 111In -IF3 prepared with either 2.5 or 10 initial molar ratios 
of CHXA”. Mice were sacrificed at 24 and 72 hour post injection mice from each group 
and blood, spleen and bone were collected, weighed, and counted in a gamma counter to 
calculate the percent of injected dose per gram (%ID/g) for each sample using a dilute 
standard. 
 
4.10 Radioimmunotherapy Study 
Female SCID mice bearing either human OS33 tumor or canine Gracie OS tumor were 
monitored until the tumor size reached ~50-100 mm3. Mice were randomized into groups of 
five for OS33 and groups of four for Gracie. There were four therapy groups for each tumor 
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type.  Group 1 was untreated; group 2 received unlabeled IF3 (cold: 12 ug IF3); group 3 
received 80 μCi of 177Lu -IF3 (8 ug, 80 μCi); group 4 received 120 μCi of 177Lu -IF3 (12 ug, 
120 μCi). The radiolabeled antibody used for therapy was prepared with a 2.5 initial molar 
excess of the CHXA”. Tumors and mouse body weights were monitored three times a week 
and tumor volume was calculated by using the formula V= L*W^2/2. Blood was collected at 
the end of each week and blood counts were measured by AcT diff Analyzer (Beckman 
Coulter). At the completion of the study, mice were humanely sacrificed and gross pathology 
was performed on the animals.   
   
5.0 RESULTS 
5.1 Expression of Full-length IF1 and IF3  
Three leading binders were previously developed in our laboratory against IGF2R using the 
phage-display technique (Broqueza et al, 2021). These binders are referred to as Fab-1, Fab-2 and 
Fab-3. Antibody constructs of the IGF2R Fab binders were expressed from mammalian vectors 
and was purified by affinity chromatography. Figure 5.1 shows the reduced version of the antibody 
wherein dithiothreitol (DTT) was added to the sample to reduce the disulfide bonds between the 
chains, showing the light chain at ~25 kDa and the heavy chain at ~50 kDa. The expected weight 
of the full length IGF2R IgG1 antibodies is ~150 kDa. IF1 and IF3 refers to the full-length antibody 







Figure 5.1. SDS-PAGE gel showing the reduced and non-reduced version of the full length IF1 














5.2 ELISA of Full-length IF1 and IF3 on Recombinant Human, Canine and Murine IGF2R 
proteins 
The expressed full length IgG1 IGF2R-specific antibodies were validated by ELISA wherein 
they were tested against human, murine and canine recombinant IGF2R. Both IF1 and IF3 bound 

















Figure 5.2. Binding of IF1 (a) and IF3 (b) antibodies to recombinant human, canine and murine 
IGF2R. (c) EC50 values in nanomolar of IF1 and IF3. 
 EC50 value (nM) 
  IF1 IF3 
Human 1 1.1 
Canine 1.4 3.2 





5.3 Flow cytometry on Human and Canine OS cells with IF1  
The binding of the full length IF1 antibody was tested using flow cytometry against different 
human and canine cell lines. 143B and D17 are human and canine commercial cell lines 
respectively, whereas OS33 is a patient-derived (PD) human OS cell line. Gracie and McKinley 
are canine PD OS cell line. Different concentrations ranging from 3 nM to 300 nM of the antibody 
was assessed to see if affinity of the antibodies is dose dependent. The RSV antibody (palivizumab) 
was used as a negative control.  
A dose-dependent shift can be observed in both 143B and OS33 cells where 300 nM 
concentration showed a prominent shift to the right indicating that the IF1 antibody is binding to 
the target protein, IGF2R, expressed by these cells. 
Figure 5.3. Flow cytometry on human OS cells with IF1 antibody. a.) 143B cells 

















Figure 5.4. Flow cytometry on canine OS cells with IF1 antibody. a.) D17 cells 
(commercially available) b.) Gracie cells (PD cell line) c.) McKinley cells (PD cell line). 
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Dose-dependent shift can also be observed in the canine OS cells. However, the shift in the 
D17 cells were not significant compared to the other cells which may indicate that D17 may be 
expressing the IGF2R in low to moderate level. 
 
5.4 microSPECT/CT of Indium-111 – CHXA” IF1 in tumor bearing nude mice  
At the beginning of the in vivo experiments, nude mice were used as they are more resistant 
to radioactivity. OS33 or Gracie tumors were grown on the right flank of the mice. Once the tumors 
were palpable, mice were injected via intravenous (IV) route with 150 μCi of 111In- IF1 that was 
conjugated with 10 times molar excess of the bifunctional chelating agent, CHXA”. We used 
different ratios of molar excess of CHXA” during conjugation of bifunctional chelator and 
radiolabeling was assessed using High Performance Liquid Chromatography (HPLC). Five molar 
excess and twenty molar excesses of CHXA” were conjugated to the IF1 antibody and were 
radiolabeled with 111In. Figure 5.5 shows that the 5 times molar excess of CHXA” is not optimal 
to get enough labelling as the second peak in the radio trace in Figure 5.5a shows that there is a 
significant amount of free 111In left after radiolabeling which is probably in the form of 111In-
CHXA” complex, resulting in a yield of 68%, whereas 20 molar excess yielded to 99% labeling. 
However, 20 molar excess might be excessive and may affect the binding of the antibody to the 





Figure 5.5. Radio-HPLC of radiolabeled 111In-IF1 conjugated 5 molar excess vs 20 molar excess 
of CHXA” 
 
MicroSPECT/CT was then performed on the mice injected with 111In-IF1and were imaged at 
24 hr, 48 hr and 7 day time point. For the 24 hr point, little radioactivity can be observed in the 
OS33 mouse. This may be due to a gut injection, therefore, making the antibody to be excreted out 
of the mouse’s system fast and no opportunity for the antibody to circulate in the blood. Because 
of this, a different mouse, bearing the same OS33 tumor, was imaged for the 48 hr and 7-day time 
point. No tumor accumulation can be observed from the images, however, there is a significant 
spleen uptake in the mice which was also observed in a previous imaging study published in 2019 
(Karkare, et al 2019). It is also possible that no tumor accumulation can be observed because the 
IGF2R expression in the tumor is suppressed by the nude mice’s immune system as these mice 
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still have their B cells intact. Therefore, we have decided to use SCID mice for the next 











Figure 5.6. MicroSPECT/CT of tumor bearing nude mice with 111In- labelled IF1. Mice were 
injected with either Gracie or OS33 cells and were imaged with 111In- IF1 conjugated with initial 
10 M excess of the CHXA” linker. Spleens are indicated by the red arrow. 
(This is a different




5.5 Biodistribution of Indium-111-CHXA” – IF1 in 143B tumor-bearing SCID mice  
Biodistribution was performed to track where the IF1 antibody uptake within the mice’s 
organ system. SCID mice bearing 143B tumors were chosen to be the mouse model in the 
biodistribution as the model was used in a previous study (Karkare, et al. 2019). The 
biodistribution shows that the IF1 antibody has a fast clearance from the blood which probably 
affects the tumor accumulation of the radiolabeled antibody. Since the IF1 antibody does not stay 
in the blood for a long time, the antibody does not circulate around the body enough to give it time 
to accumulate in the tumor. However, the tumor specificity of IF1, which can be calculated by 
dividing the %ID/g (injected dose/gram) value of the blood from the tumor, shows a higher value 
compared to 2G11 and RSV as shown in figure 5.8. 
Figure 5.7. Biodistribution of 111In-IF1 (6 ug, 30 μCi), 111In-2G11 (Positive control, 6 ug, 30 μCi) 
or 111In-RSV (Negative control, 6 ug, 30 μCi), antibodies in 143B tumor bearing SCID mice. All 




 Figure 5.8. Biodistribution of IF1 and control antibodies. % of injected dose per gram (ID/g) 
values of IF1, 2G11, and RSV antibodies are shown. All antibodies were radiolabeled with 111In 
conjugated with initial 10 molar excess of the CHXA” linker. 
 
5.6 IF3 binding to human and canine patient derived OS cells by flow cytometry 
Given the lack of sufficient tumor uptake in imaging, we pursued an alternative lead antibody 
against IGF2R, IF3. Flow cytometry was performed to test the affinity of the IF3 antibody against 
human and canine OS cells. From the graph, one can confer that there is a significant shift of the 
IF3 antibody in all the OS cell lines, indicating that IF3 binds to the IGF2R proteins that are 
expressed by these cells. We have decided to test the IF3 antibody biodistribution in concurrence 





Figure 5.9. Flow cytometry of human and canine OS cells with IF3 antibody. a.) OS33 cells b.) 
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5.7 Small-scale biodistribution to determine the effect of excess CHXA” (2.5 AND 10 M 
excess) on the clearance of IF1 and IF3 in the blood 
An experiment previously performed in Dr. Dadachova’s lab tested the influence of the 
bifunctional chelator to the blood clearance of an antibody wherein they observed that the higher 
the molar excess of the linker, the faster the radiolabeled antibody gets cleared from the blood. 
With this information, we decided to perform a pilot biodistribution study of the IF1 and IF3 
antibodies with 2.5 molar excess versus 10 molar excess to determine the effect of the excess 
CHXA” on the antibodies’ blood clearance.  Before the biodistribution, ELISA was performed to 
test whether the conjugation of the antibodies to CHXA” will significantly alter their binding 
affinity to IGF2R (Figure 5.10). ELISA result shows that conjugated antibodies did not 
significantly decrease its affinity to IGF2R.  
Figure 5.10. ELISA of unconjugated vs conjugated (2.5 M vs 10 M excess of CHXA”) of IF1 
and IF3 antibodies (Broqueza et al, 2021). 
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The pilot biodistribution shows that IF3 stays in the blood longer than IF1. Moreover, we 
can confer that the amount of the excess linker plays a role in making the antibody stay in the 
circulation longer as in both antibodies, the 2.5 M CHXA” excess has a higher %ID/g compared 
to the 10 M excess. Therefore, we determined to test the IF3 conjugated with 2.5 M excess of 
CHXA” for imaging. We injected a SCID mouse bearing 143B tumor via intraperitoneal (IP) route 
with 111In-IF3 and imaged it at 24 hr, 48 hr, and 6 day time point. As seen in figure 5.12, tumor 
accumulation can be observed at the 48 hr time point as shown by the red circle, highlighting the 
tumor uptake. Therefore, we moved the project forward using the IF3 antibody and conjugating it 
with 2.5 M excess of the CHXA” linker for the consecutive experiments.  
Figure 5.11. Biodistribution of 111In- IF1 vs 111In- IF3 antibodies conjugated with initial 2.5 vs 10 
M initial molar excess of CHXA” linker in SCID mice. (Broqueza et al, 2021) 
38 
 
The conjugated antibodies were also sent to the University of Alberta mass spectrometry 
facility to determine the CHXA”/antibody ratio using the matrix-assisted laser 
desorption/ionization (MALDI) method. MALDI results showed that the IF1-CHXA”-2.5 M and 
IF1-CHXA”-10 M excess has a CHXA”/antibody ratio of 0.96 and 2.9 respectively whereas IF3-
CHXA”-2.5 M and IF3-CHXA”-10 M excess has 0.91 and 3.4. 
 
 
Figure 5.12. MicroSPECT/CT of 143B tumor bearing SCID mice with 111In- labelled IF3 
conjugated with initial 2.5 M excess of the CHXA” linker. Tumor is highlighted with a red 




24 hr point 48 hr point 6 day point
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5.8 microSPECT/CT of OS33 and Gracie tumor bearing SCID mice labelled with Indium-
111 – CHXA” IF3  
Figure 5.13. MicroSPECT/CT of Gracie tumor bearing SCID mice with 111In- IF3. Tumor 
accumulation is indicated by the white circles and spleens are indicated by red arrows. 
 
Since we have observed tumor uptake in the SCID mouse bearing the 143B tumor, we went 
ahead to do another imaging study with the IF3 antibody. Three groups of mice were injected with 
the human and canine PD cells. Group one was OS33, group 2 was Gracie and group 3 was 
McKinley. Palpable tumors grew in both OS33 and Gracie groups ~2-3 weeks and were imaged 
with 111In-IF3 at 24 and 48 hr time point. Unfortunately, no tumors grew in the McKinley group, 
indicating that the cell line may not be tumorigenic.  
In figure 5.13, Gracie mice were injected with the radiolabeled 111In-IF3 via IP route. 
Tumor accumulation can be observed on the right flank of the mice where the cells were injected. 
However, significant radioactivity can be observed around the injection site and the spleen was 
40 
 
not showing as much radioactivity as expected which might indicate that the radioactive antibody 
might have pooled around the site of injection and did not circulate around the body for it to 
accumulate more on the tumor. Therefore, we decided to inject the next set of mice via IV route 
to see a clearer image of the tumor accumulation as seen in figures 5.15 and 5.16. We have also 
performed HPLC as seen in figure 5.14 to test whether the radioactivity observed in figure 5.13 
were macroaggregates from the radiolabeled antibody. However, this is not the case as the HPLC 
data shows that the radiolabeled antibody is pure and has no macroaggregates. 















Figure 5.15. MicroSPECT/CT of OS33 tumor bearing SCID mice with 111In- labelled IF3. Tumor 











Figure 5.16. MicroSPECT/CT of Gracie tumor bearing SCID mice with 111In- labelled IF3. Tumor 
accumulation is indicated by the white circles and spleens by the red arrows. (Broqueza et al, 2021) 
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5.9 Radioimmunotherapy study in SCID mice bearing OS33 or Gracie tumor 
OS33 tumor bearing mice were randomized into groups of five and Gracie tumor bearing 
mice were randomized into groups of four. There were four therapy groups for each tumor type.  
Group 1 was untreated; group 2 received unlabeled IF3 (cold, 12 μg IF3); group 3 received 80 μCi 
of 177Lu -IF3 (8 μg, 80 μCi); group 4 received 120 μCi of 177Lu -IF3 (12 μg, 120 μCi).  Mice were 
treated with 177Lu- IF3 via IP injection when tumor volume reached approximately 50-100 mm3. 
Mice were then monitored by performing tumor measurements and measuring the weights three 
times a week. In Figure 5.17, the tumor volume was averaged on each day point and normalized 




Table 5.1. Average volumes of OS33 and Gracie tumors in SCID mice prior to therapy. 
 
In both therapy studies, there is a continuous growth of the tumors in the untreated and 
cold groups. For the OS33 groups, there is tumor suppression observed in the treated groups 
compared to the control groups. Mice in both the 80 μCi and 120 μCi treated group were sacrificed 
by day 11 as the mice showed symptoms of radiotoxicity and some of the tumors appeared to be 
necrotic. Two mice from 120 μCi succumbed to radiotoxicity effects by day 11, indicating that 
120 μCi is beyond the maximum tolerated dose (MTD). For the Gracie therapy, tumor regression 
OS33 Gracie
Group 1 (Untreated) 63.7213 55.82625
Group 2 (Cold IF3) 52.5299 91.288125
Group 3 (80 µCi Lu-177-IF3) 76.6458 79.895
Group 4 (120 µCi Lu-177-IF3) 61.1318 85.258875
Average Tumor Volume (mm3)
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can be observed by day 2 of the 120 μCi treated group.  However, just as in the OS33 group, two 
mice bearing the Gracie tumor succumbed to radiotoxicity effects in the 120 μCi group. Mice in 
the Gracie 80 μCi group has also succumbed to radiation side effects and died by day 13. Endpoints 
of mice were defined by the Humane Intervention Protocol (HIP) and were met by weight loss, 
lethargy, rapid breathing and abnormal posture. The study was terminated as both treatment groups 
either met the HIP endpoint or succumbed to radiotoxicity effects. 
White blood cells (WBC), red blood cells (RBC), and platelets levels were collected 
weekly via tail vein puncture (Figure 5.18). WBCs and platelet levels are significantly lower in 
the treated group compared to the control group by Week 1 in both the OS33 and Gracie group. 
Moreover, RBC levels of the treated Gracie groups decreased by Week 2. If the OS33 treated 
groups lasted for another week, it is expected that their RBC levels would also decrease as was 
























Figure 5.17. Radioimmunotherapy of OS33 (a) and Gracie (b) tumor-bearing SCID mice with 
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Gross pathology was also performed on the mice. Blood clotting at the tumor site was 
observed in both the OS33 and Gracie treated groups. However, the OS33 group showed a more 
prominent blood clotting (Figure 5.19) which may be due to its higher tumor volume. Red spots 
in the liver were observed in the 120 μCi groups which may indicate liver damage. Spleens in the 
120 μCi treated groups were also significantly smaller compared to the treated once again pointing 














Figure 5.19. Gross pathology of mice treated with 120 μCi 177Lu- IF3. (a) Blood clotting around 






The long-term goal of this research project is to develop RIT for the dual treatment of 
human and canine OS. We aim to achieve this by developing novel fully human antibodies 
against IGF2R using the phage-display technique with future projects involving caninization 
of antibodies and development of novel canine antibodies against IGF2R. 
 IGF2R is a cell surface receptor which modulates the activity of the insulin-like growth 
factor II (IGF-II) protein by sequestering the growth factor for internalization and degradation 
as well as lysosomal enzyme sorting. IGF2R was chosen to be the target protein for this project 
as it has been shown that this protein is overexpressed in human OS cells (Hassan et al, 2011) 
and canine OS tumors (Karkare et al, 2019).  
To select for IGF2R-specific binders, domains 11-13 of recombinant human, murine and 
canine IGF2R were expressed and purified. These domains where chosen, as a crystalized 
structure of the IGF-II/IGF2R complex (Brown et al, 2008) shows distinct conserved residues 
where the ligand interacts with the receptor from domain 11, which acts as the main binding 
site of IGF-II and domain 13, which facilitates strong ligand receptor interaction. A sequence 
alignment of the human, murine, and canine IGF-II binding region, containing domains 11-
13, showed that this region is highly conserved among these species with 82% sequence 
identity (Broqueza et al, 2021). These domains served as a conserved template for 
development of antibodies with cross reactivity across the species, enabling a comparative 
oncology study.  
An antibody Fab fragment library developed in Dr. Uppalapati’s lab was used to select for 
IGF2R-specific human mAbs. After several rounds of selection, three leading binders against 
IGF2R were developed. The binders (hereby known as Fab-1, Fab-2, and Fab-3) were initially 
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expressed as Fab fragments of the antibodies. We also expressed these antibodies as full-
length IgG1 molecules. After these antibodies were expressed as full-length IgG1 proteins, the 
nomenclature of each binder was thereby referred to as IF1 (from Fab-1), IF2 (from Fab-2) 
and IF3 (from Fab-3). After expression of the antibodies in Expi293F mammalian cells, IF2 
yielded low concentrations compared to IF1 and IF3, therefore, the second leading binder was 
put on hold and the project moved forward using IF1 and IF3. 
IF1 and IF3 both demonstrated similar affinity against recombinant IGF2R proteins and 
bound specifically to different OS cell lines. Non-invasive imaging with microSPECT/CT was 
initially done in nude mice bearing either OS33 or Gracie tumor. Mice models bearing patient-
derived xenografts of human or canine tumor cell lines were desired due to their clinical 
relevance. This was the rationale for using both the human OS33 and canine Gracie PDXs for 
tumor imaging and treatment.  
IF1 did not show any tumor accumulation in nude mice bearing the human and canine OS 
tumor at any time point. However, the images demonstrated spleen targeting which was also 
observed in a previous study as the spleen also expresses IGF2R (Karkare et al., 2019). We 
hypothesized that the reason for lack of tumor accumulation with IF1 was that the immune 
system of the nude mice may be suppressing the IGF2R expression on tumors, as these mice 
are not as immunocompromised as SCID mice. Therefore, we decided to use SCID mice, 
which lacks both B and T cells, for the induction of OS tumor to confirm the expression of 
IGF2R for therapy and imaging with IF1 and IF3. 
The pharmacokinetics of the radiolabeled IF1 antibody was assessed through a 
biodistribution study performed in SCID mice bearing human OS 143B tumors.  Indium-111, 
with a half-life of 2.83 days, was used for the biodistribution and imaging studies as it emits 
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high energy gamma emissions at 173 keV and 247 keV, which are easily visualized on SPECT 
imaging. 
The data from the IF1 biodistribution demonstrated high IF1 blood clearance, but high 
tumor specificity compared to the 2G11 and RSV controls (Figures 5.7 and 5.8). In the context 
of imaging agents, fast blood clearance can possibly be an asset with high target to non-target 
ratio, but excessive clearance in the context of therapy might prevent mAbs from attaining 
significant tumor uptake and reduce the efficacy of RIT. Due to this, we have decided to test 
the alternative mAb against IGF2R, IF3.  A small-scale biodistribution study comparing the 
blood clearance of IF1 and IF3 and the influence of the excess bifunctional chelator, CHXA”, 
to the blood clearance of the antibodies showed that minimizing the number of the CHXA” 
linker molecules helped both antibodies to stay in the circulation longer. This agrees with 
previous in-house data showing that increased CHXA” linker ratio to mAb increases blood 
clearance. IF3 also showed a longer blood half-life compared to IF1. Due to this, IF3 
conjugated with 2.5 molar excess of the CHXA” linker was used in subsequent experiments. 
The binding of the IF3 antibody in vivo was confirmed by microSPECT/CT imaging which 
shows tumor accumulation in both OS33 and Gracie mouse models.  (Figure 5. 15 and 5.16).  
Lutetium-177, a beta-emitting radioisotope with a half-life of 6.7 days, was used for the 
therapy on SCID mice bearing human and canine OS tumors. Moreover, 177Lu is a theranostic 
radioisotope, meaning it can be used for imaging due to its gamma emissions and as a 
therapeutic isotope due to its beta emissions. Two doses of radioactivity, 80 μCi and 120 μCi 
of 177Lu-IF3 was tested. A low dose of 80 μCi was shown as an effective dose in a previous 
study (Karkare et. al., 2019). Due to the increased IF3 clearance compared to the commercial 
anti-IGF2R mAb 2G11, we hypothesized that increasing the dose to 120 μCi may potentially 
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help increase the efficacy of RIT in the scenario that 80 μCi of 177Lu does not show significant 
tumor suppression. 
For the OS33 groups, there was a continuous tumor growth in both the untreated and cold 
group. Tumor inhibition was observed in low and high dose 177Lu-IF3-CHXA” in both the 
human and canine tumor groups. An important note, however, is that the initial tumor volume 
of the untreated Gracie group was significantly smaller compared to the cold and treated 
groups and therefore may not fully represent the inhibitory ability of 177Lu-IF3-CHXA”. 
Hence, we based our conclusions of tumor suppression in the treated groups on the cold IF3 
treated groups as the initial tumor volume in this group was similar to the treated groups. 
Low red and white blood cell counts was observed in all the treated groups which is a 
common side effect of radioimmunotherapy. Low red and white blood cell counts may be due 
to the radiation affecting the hematopoietic stem cells in the bone marrow or due to 
accumulation of radiation in the spleen causing hemolysis. Regrettably, some mice succumbed 
to radiotoxicity side effects in the high dose 120 μCi 177Lu-IF3 groups, indicating that MTD 
for this antibody-isotope combination was exceeded. Moreover, gross pathology shows 
possible sign of liver damage in the 120 μCi groups, clotting issues around the tumor, and a 
decreased spleen volume. 
One possible solution for the future studies to overcome and decrease the number of deaths 
in the treated groups is to lower the radioactivity dose and to switch to a more radioresistant 
mice such as nude mice. Co-administration of the cold and the radiolabeled antibody may also 
increase the efficacy of the therapy as a recently published paper demonstrated co-




This project holds the promise for RIT as the treatment for OS. However, some limitations 
should be taken into consideration. The use of severely immunocompromised mice serves as 
an inherent curb as it voids the immune- mediated response and does not represent a complete 
mimic of a canine or a human immune system. With this limitation, there is a clear need the 
need for preclinical models of human or canine tumors in more immunocompetent mice. 
Moreover, pharmacokinetics of the antibodies still needs to be assessed especially with the 
fast blood clearance. The immediate clearance of the antibodies, specifically with IF1, may be 
explained by target-mediated drug disposition (TMDD) as IGF2R has high expression in 
spleen of mouse models. The difference between IF1 and IF3 is that the latter has lower 
affinity towards murine IGF2R. Since we are performing the experiments in mice models, IF3 
slightly has a longer half-life in the blood compared to the IF1 antibody which gets degraded 
out of the system. 
High spleen uptake in the imaging experiments can also be a cause of concern in this study. 
However, a recently published paper (Karkare et al, 2019) using RIT for OS have shown that 
no histological spleen damage, together with no abnormalities in the liver enzymes and kidney 
biomarkers, can be observed in the RIT treated mice at 80 µCi level.  
 
7.0 CONCLUSION AND FUTURE WORK 
With the lack of new effective therapies for OS, RIT presents a promising novel approach 
to therapy for OS. To date, only unlabeled mAbs for immunotherapy have been evaluated in 
clinical trials for the therapy of OS. Moreover, in some preclinical studies, 153Samarium-
EDTMP or polymeric radiolabeled phosphonates was suggested for targeted therapy of OS. 
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Novel human antibodies that bind to human, canine and murine IGF2R are promising reagents 
for further development for RIT of human and canine OS patients.  
Future work: Pharmacokinetics and dosimetry of the radiolabelled antibodies still needs 
to be assessed for RIT. Increasing the half-life of the IF3 antibody in the bloodstream and 
increasing tumor accumulation may lead to better therapeutic effect. To help decrease major 
side effects observed in the mice therapy such as blood clotting around the tumor, low blood 
levels, and a shrunken spleen, a possible solution may be to perform blocking or co-
administration of the unlabeled IF3 body with the radiolabeled one.  Addressing these issues 
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